Trial Profile
Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan, A Retrospective Nhia Database Analysis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary) ; Pazopanib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Pfizer
- 11 Apr 2018 Status changed from active, no longer recruiting to completed.
- 11 Sep 2017 Planned primary completion date changed from 1 Jul 2017 to 31 Dec 2017.
- 01 Nov 2016 Status changed from not yet recruiting to active, no longer recruiting.